| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8466586 | Cytotherapy | 2018 | 8 Pages |
Abstract
HBsAg-CAR T cells have anti-HBV activity in an authentic preclinical HBV infection model. Our results warrant further preclinical exploration of HBsAg-CAR T cells as immunotherapy for HBV.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Robert L. Kruse, Thomas Shum, Haruko Tashiro, Mercedes Barzi, Zhongzhen Yi, Christina Whitten-Bauer, Xavier Legras, Beatrice Bissig-Choisat, Urtzi Garaigorta, Stephen Gottschalk, Karl-Dimiter Bissig,